NetScientific PLC Glycotest Strengthens Intellectual Property Reach
July 07 2017 - 2:00AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
07 July 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Glycotest(TM) Strengthens its Intellectual Property Reach by
Expanding its United States, European and Australian Patent
Portfolio
London, UK - 07 July 2017 - NetScientific plc ("NetScientific",
AIM:NSCI), the transatlantic healthcare IP commercialisation Group,
announces that a European patent exclusively licensed to one of its
portfolio companies, Glycotest, has been granted. In addition,
United States and Australian patents have been allowed. These
patents will significantly extend protection for Glycotest's core
technology for early detection of life threatening liver
disease.
These patents expand the portfolio of six previously granted
patents (three US and three ex-US patents) to strengthen protection
of Glycotest's biomarker and assay technology. Glycotest now holds
patents in the US, Europe, Japan and Australia covering the use of
over 50 unique glycoprotein biomarkers and related assay technology
for the diagnosis of liver cancers and other liver diseases.
As announced on 26 June 2017, the Company is aiming to close a
Series A round within the second half of 2017.
NetScientific holds an 87.5% stake (67% on a fully diluted
basis) in Glycotest.
Glycotest's lead product, HCC Panel, continues to significantly
outperform the current dominant blood test (AFP) in separate 208
and 127 patient head-to-head clinical studies.
Commenting on the news, NetScientific's Chief Executive Officer
and Chairman of Glycotest, Francois R. Martelet said: "We are very
pleased to announce international strengthening of the IP landscape
controlled by Glycotest in the field of liver diagnostics. The
patents provide the foundation for future value enhancement and
represent a critical step on Glycotest's road to commercialisation.
We look forward to further clinical validation of the Glycotest
platform in H2 2017."
The full text of the announcement from Glycotest can be found
below.
For more information please contact:
NetScientific
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
info@netscientific.net
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
netscientific@consilium-comms.com
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
Glycotest Inc.
Lawrence Cohen
Office: +1 646 722 4339
larry.cohen@glycotest.com
About NetScientific:
NetScientific is an IP commercialisation group focused on
healthcare with an investment strategy focused on sourcing, funding
and commercialising technologies that significantly improve the
health and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
Glycotest(TM) Intellectual Property Portfolio Expanded by United
Sates, European and Australian Patents
New York, NY-July 07, 2017-Glycotest, Inc. announced today that
a European patent has been granted and additional United States and
Australian patents have been allowed. Together these patents will
extend protection of the Company's core technology for early
detection of life threatening liver disease.
Glycotest is a private liver disease diagnostics company
commercializing new and unique blood tests for liver cancers and
fibrosis-cirrhosis. The Company's mission is to reduce mortality
and increase survival for the growing population at risk from
serious liver diseases. Glycotest employs unique non-invasive blood
tests based on proprietary serum biomarkers, biomarker panels and
assay technology that exploit novel sugar-based disease signal
chemistry.
The granted European and allowed United States and Australian
patents announced today join six other patents previously granted
in the United States, Japan and Australia which have been licensed
exclusively and on a worldwide basis to Glycotest by Drexel
University College of Medicine and the Blumberg Institute of the
Hepatitis B Foundation, both in the Philadelphia area. These
patents cover the use of over 50 unique glycoprotein biomarkers as
well as related assay technology for the diagnosis of liver cancers
and other liver diseases. Together the granted patents and the
additional pending applications protect Glycotest's proprietary
liver disease diagnostic platform.
Commenting on these developments, Glycotest's Chief Executive
Officer Lawrence Cohen said, "The Glycotest patent portfolio is
expanding in both the breadth of our technology protection and the
jurisdictions in which we have granted patents. We anticipate
continued good news regarding our intellectual property portfolio
which we expect to form the basis of a strong position in the liver
disease diagnostics space."
- Ends -
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company
commercializing novel clinical laboratory testing services for
patients at risk for liver cancers and fibrosis-cirrhosis. The
Company was founded in 2012 on proprietary technology that
originated at the Philadelphia area institutions Baruch S. Blumberg
Institute and Drexel University College of Medicine. Learn more at
www.glycotest.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABSGDRDXGBGRL
(END) Dow Jones Newswires
July 07, 2017 02:00 ET (06:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2023 to Apr 2024